Theranostics · 2022 · 41 citations · 25 references
Life SciencesCell BiologyMolecular BiologyCell SignalingSignal TransductionVascular SurgeryAngiogenesisEndothelial ActivationEndothelial DysfunctionPeripheral Arterial DiseaseAngiogenic ResponseBlood FlowEndothelial ProliferationPeripheral Artery Disease RevascularizationSphingosine 1-Phosphate Receptor Modulation
Aims: It is important to understand the mechanism that regulates post-ischemic angiogenesis and to explore a new therapeutic target for an effective improvement of revascularization in peripheral artery disease (PAD) patients. Post-ischemic angiogenesis is a highly orchestrated process, which involves vascular endothelial cells (ECs) proliferation, migration and assembly into capillaries. We found a significant reduction of S1pr2 (sphingosine 1-phosphate receptor 2) in endothelial cells after hindlimb ischemia (HLI). We thus hypothesized that EC-S1pr2 might be involved in the regulation of post-ischemic angiogenesis and blood flow recovery during peripheral arterial disease (PAD). Methods and Results: We generated both EC-specific S1pr2 loss-of-function and S1pr2 gain-of-function mice. Our study showed that EC-specific S1pr2 loss-of-function significantly enhanced post-ischemic angiogenesis and improved blood flow recovery upon femoral artery ligation, whereas the EC-specific S1pr2 gain-of-function severely hindered post-ischemic angiogenesis and reduced blood flow recovery in ischemic limbs. We next identified that S1pr2 inhibited AKT/eNOS signaling pathway, and thus inhibited EC proliferation/migration and angiogenic activity. As expected, pharmacological inhibition of S1pr2 by JTE013 improved post-ischemic angiogenesis and improved blood flow perfusion after femoral artery ligation. Moreover, we developed RGD-peptide magnetic nanoparticles packaging S1pr2-siRNA which specifically targeted ECs and achieved an efficient silencing of S1pr2 expression in ECs in vivo. This EC-targeted strategy to dampen S1pr2 significantly enhanced post-ischemic angiogenesis and boosted blood perfusion after HLI, supplying a novel therapy target for patients with peripheral arterial disease. Conclusions: This present study demonstrates that EC-expressing S1pr2 tightly controls post-ischemic angiogenesis and blood flow perfusion recovery. This research provides a novel strategy for EC-target knockdown of S1pr2 as a new therapeutic intervention for patients with peripheral artery disease.
25
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Stefanie Dimmeler, Ingrid Fleming, Beate Fißlthaler et al. · Nature · 1999 · 3.6K citations
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Yingdi Wang, Masanori Nakayama, Mara E. Pitulescu et al. · Nature · 2010 · 1.3K citations
Andreas Papapetropoulos, Guillermo García‐Cardeña, Joseph A. Madri et al. · Journal of Clinical Investigation · 1997 · 1.2K citations · Full text
Impaired Arteriogenic Response to Acute Hindlimb Ischemia in CD4-Knockout Mice
Eugenio Stabile, Mary Susan Burnett, Craig Watkins et al. · Circulation · 2003 · 262 citations · Full text